Table 6.
Clinical studies on combination of radiotherapy and CSC-targeting therapies
| Target | NCT Number | Tumor type | Phases | Conditions | Enrollment | Interventions | Study Results | Study Status |
|---|---|---|---|---|---|---|---|---|
| OCT4, SOX2, Nanog, ABCB1, ABCG2 | NCT02423811 | Esophageal cancer | II | Newly diagnosed stage II and III esophageal squamous cell carcinoma | 20 | Fursultiamine + Concurrent Chemoradiotherapy | NA | Completed |
| AKT/ERK | NCT04854044 | Glioblastoma | I | Recurrent glioblastoma | 0 | Presurgery ONC201 + Radiotherapy | NA | Withdrawn |
| ALDH | NCT01777919 | Glioblastoma | II | Newly diagnosed glioblastoma | 32 | Disulfiram/copper before chemo-radiotherapy | NA | Unknown |
| Periventricular stem cell niche | NCT02039778 | Glioma | NA | Newly diagnosed high grade glioma after surgery | 4 | Radiotherapy + Temozolomide | All 4 patients had adverse events and did not complete the study | Completed |
| Notch | NCT01119599 | Glioma | I | Newly diagnosed glioma | 22 | RO4929097 + Radiotherapy + Temozolomide | NA | Completed |
| AKT | NCT05172245 | Head and neck squamous cell carcinoma | I | Locally advanced head and neck squamous cell carcinoma | 46 | Ipatasertib + Chemo-radiotherapy | NA | Recruiting |
| Notch | NCT01217411 | Brain metastases | I | Newly diagnosed metastatic disease to the brain | 5 | RO4929097 + Radiotherapy | Study terminated early due to low accrual and discontinuation of investigational study drug. | Terminated |
| AKT | NCT00694837 | Glioblastoma | I | Newly diagnosed glioblastoma | 6 | Nelfinavir + Radiotherapy + Temozolomide | NA | Completed |
| AKT | NCT01068327 | Pancreatic cancer | I | Locally advanced pancreatic cancer | 46 | Presurgery Nelfinavir + Radiotherapy | Median OS: 14.4 months | Completed |
| AKT | NCT03256916 | Cervial cancer | III | Untreated locally advanced cervical cancer | 348 | Nelfinavir + Chemo-radiotherpay | NA | Recruiting |
| AKT | NCT01485731 | Cervical cancer | I | Locally advanced cervical cancer | 8 | Nelfinavir + Chemo-radiotherpay | NA | Completed |
| PI3Kα | NCT02537223 | Head and neck squamous cell carcinoma | I | Locally advanced head and neck squamous cell carcinoma | 9 | BYL719 + Chemo-radiotherapy | NA | Completed |
| PI3K | NCT02128724 | Non-small cell lung cancer | I | Any-stage non-small cell lung cancer | 21 | BKM120 + Radiotherpay | 3 of 21 patients had serious adverse events | Completed |